9-Oct-2026
Claritev Selected by GDIT to Support CDC's World Trade Center Health Program
Business Wire (Tue, 22-Sep 9:00 AM ET)
Claritev Releases 2025 Corporate Responsibility Report
Business Wire (Thu, 17-Sep 9:00 AM ET)
Claritev Appoints Ben Letham to its Board of Directors
Business Wire (Tue, 15-Sep 9:00 AM ET)
Claritev Cares Helps Rural Patients Get Critical Care Closer to Home
Business Wire (Thu, 10-Sep 9:00 AM ET)
Claritev Corporation Announces Participation in Upcoming Events
Business Wire (Thu, 27-Aug 8:00 AM ET)
Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients
Business Wire (Mon, 17-Aug 9:00 AM ET)
Claritev Corporation Reports Second Quarter 2026 Results
Business Wire (Fri, 7-Aug 5:00 AM ET)
Claritev Corporation Announces Participation in Canaccord Genuity 46th Annual Growth Conference
Business Wire (Tue, 4-Aug 8:00 AM ET)
Claritev Demonstrates Market Leadership as Federal No Surprises Act Disputes Reach Record Levels
Business Wire (Thu, 30-Jul 9:00 AM ET)
PRNewswire (Tue, 28-Jul 9:01 AM ET)
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Claritev Class A trades on the NYSE stock market under the symbol CTEV.
As of October 9, 2026, CTEV stock price climbed to $24.66 with 120,264 million shares trading.
CTEV has a beta of 2.58, meaning it tends to be more sensitive to market movements. CTEV has a correlation of 0.04 to the broad based SPY ETF.
CTEV has a market cap of $417.92 million. This is considered a Small Cap stock.
Last quarter Claritev Class A reported $257 million in Revenue and -$3.49 earnings per share. This beat revenue expectation by $12 million and missed earnings estimates by -$3.73.
The top ETF exchange traded funds that CTEV belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.
CTEV has underperformed the market in the last year with a return of -57.7%, while the SPY ETF gained +17.1%. In the last 3 month period, CTEV fell short of the market, returning -25.0%, while SPY returned +3.8%. However, in the most recent 2 weeks CTEV has outperformed the stock market by returning +6.3%, while SPY returned +0.9%.
CTEV support price is $22.76 and resistance is $25.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTEV shares will trade within this expected range on the day.